Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;33(3):e13311.
doi: 10.1111/dth.13311. Epub 2020 Mar 30.

Oral erythromycin in pityriasis lichenoides chronica and pityriasis lichenoides et varioliformis acuta

Yunliu Chen  1 , Mutong Zhao  1 , Xin Xiang  1 , Zhaoyang Wang  1 , Zigang Xu  1 , Lin Ma  1
Affiliations

Oral erythromycin in pityriasis lichenoides chronica and pityriasis lichenoides et varioliformis acuta

Yunliu Chen et al. Dermatol Ther. 2020 May.

Abstract

Pityriasis lichenoides (PL) is an uncommon cutaneous disorder. Oral erythromycin is proposed to be effective in treating the disease. Here, we reported 16 pediatric patients with PL and systematically reviewed published literatures on erythromycin treatment response in pediatric PL patients, to observe the different treatment response to erythromycin in the pityriasis lichenoides chronica (PLC) and the pityriasis lichenoides et varioliformis acuta (PLEVA) groups. Sixteen patients, 8 with PLC and 8 with PLEVA, were treated with erythromycin. In the PLC group, 25% (n = 2) patients responded to erythromycin, while in the PLEVA group, 87.5% (n = 7) patients responded to erythromycin. The response rate was higher in the PLEVA group than the PLC group (P =.05). No side effect was reported in the 16 patients. A total of 34 children including 16 from our studies were included for further descriptive analysis, in which 12 had PLC and 22 had PLEVA. In the PLC group, 41.7% (n = 5) of patients responded to erythromycin while in the PLEVA group, 90.9 % (n = 20) of patients responded. The response rate was higher in the PLEVA group than the PLC group (P = .004). In conclusion, erythromycin is effective and safe in the treatment of children with PL, and erythromycin was more effective in patients with PLEVA than PLC.

Keywords: erythromycin; pityriasis lichenoides chronica (PLC); pityriasis lichenoides et varioliformis acuta (PLEVA).

PubMed Disclaimer

References

REFERENCES

    1. Geller L, Antonov NK, Lauren CT, Morel KD, Garzon MC. Pityriasis lichenoides in childhood: review of clinical presentation and treatment options. Pediatr Dermatol. 2015;32:579-592.
    1. Khachemoune A, Blyumin ML. Pityriasis lichenoides: pathophysiology, classification, and treatment. Am J Clin Dermatol. 2007;8:29-36.
    1. Cuellar-Barboza A, Cardenas-De La Garza JA, Villarreal-Villarreal CD, et al. Efficacy of phototherapy in pityriasis lichenoides chronica of dark skin: a retrospective study from a tertiary center in Mexico. Dermatol Ther. 2018;31:e12734.
    1. Ersoy-Evans S, Greco MF, Mancini AJ, Subasi N, Paller AS. Pityriasis lichenoides in childhood: a retrospective review of 124 patients. J Am Acad Dermatol. 2007;56:205-210.
    1. Gelmetti C, Rigoni C, Alessi E, Ermacora E, Berti E, Caputo R. Pityriasis lichenoides in children: a long-term follow-up of eighty-nine cases. J Am Acad Dermatol. 1990;23:473-478.

Publication types

LinkOut - more resources